Success Stories: Backed by NAILG, Translational Computational Oncology Researcher Received EB-1A in Just 15 Days

Posted by wegreened on August 21, 2025 in EB1 Green Card, Medicine (Pharmaceutics, Pharmacology, Oncology, Pharmacognosy, Biomedical Engineering, Biomedicine)

Client’s Testimonial:

“I also want to express my deep appreciation for my attorney, for his support and guidance throughout this process.”

On May 13^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Research Fellow in the Field of Translational Computational Oncology (Approval Notice).

General Field: Translational Computational Oncology

Position at the Time of Case Filing: Postdoctoral Research Fellow

Country of Origin: Iran

State of Residence at the Time of Filing: Texas

Approval Notice Date: May 13^th, 2025

Processing Time: 15 days (Premium Processing Requested)

Case Summary:

A recognized leader in translational computational oncology has reshaped the landscape of drug discovery, targeted therapies, and vaccine design. Her work has produced novel computational frameworks for drug repurposing, molecular docking simulations, and precision oncology, offering efficient, cost-effective paths to combat complex diseases. Her contributions are especially vital to addressing global challenges in cancer care and immunotherapy.

Her research addresses urgent questions that affect millions: how can we accelerate cancer treatment development, repurpose existing pharmaceuticals to treat new conditions, and deploy computational tools for smarter vaccine design? Through innovative answers to these questions, our client has earned a reputation as an authority in her field.

International Recognition and Scholarly Influence

● 7 peer-reviewed journal articles, including 2 as first author

● 377 citations across 56 countries

● Ranked among the top 1% most highly cited researchers in vaccine therapy over the past decade

● 40 completed peer reviews, confirming her standing as a trusted expert among scientific journals

● Funding support from the Biotechnology Development Council of Iran, highlighting international recognition of her work

A Strategic Petition by NAILG

To bring her expertise to the U.S., she collaborated with the North America Immigration Law Group (NAILG) to file her EB-1A petition. NAILG developed a comprehensive legal strategy that emphasized not only the originality and influence of her contributions but also their national importance, particularly in the fields of precision medicine, vaccine innovation, and therapeutic design. The petition presented a clear, compelling case that met the USCIS’s stringent EB-1A criteria without triggering a Request for Evidence (RFE).

Approved in Just 15 Days with No RFE

Thanks to her exceptional track record and NAILG’s expert petitioning, our client’s EB-1A case was approved in just 15 days under Premium Processing. This swift, challenge-free outcome underscores both the strength of her achievements and the persuasive clarity of her petition.

Endorsement from Field Authorities

"In summary, [client] continues to make valuable contributions to computational vaccine design, antiviral drug repurposing, and molecular modeling, underscoring her sustained leadership in the translational computational oncology field. In particular, her work plays a critical role in advancing infectious disease treatment and vaccine development, making it essential to support her continued research."

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%